Background
Liddle's syndrome (Ls) is a monogenic form of hypertension simulating a mineralocorticoid excess, and is currently suspected in young hypokalemic hypertensives. the aims of the study were: (i) to evaluate the clinical phenotype of Ls in a newly identified Italian family of sicilian origin carrying a gain-of-function mutation of the β subunit of the epithelial sodium channel (ENaC) (P617L) previously reported by our group in an apparently unrelated sicilian patient presenting the typical phenotype of Ls including hypokalemia; (ii) to determine whether an unknown biological relationship exists between the newly identified family and the family of the proband previously reported.
Methods
genetic analysis was performed in the present family, in the individual in which the βP617L mutation was first observed, and in his relatives. results βP617L mutation was identified in the proband and in three maternal relatives. None of them showed hypokalemia. Mild to severe early onset hypertension and left ventricular hypertrophy were present in all of them. analysis of mitochondrial DNa (mtDNa) and Y chromosome profiles in the present family and in the proband's family previously reported showed the absence of a relationship between them. the availability of only one carrier of the mutation in one of the two families meant that a genetic analysis able to assess a founder effect was not feasible.
original contributions Normokalemic Liddle's Syndrome same PY motif in the C-terminus of β-subunit, 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] resulting in increased ENaC activity. These PY motifs mediate an inhibitory regulation of ENaC apical expression, which occurs in physiological conditions characterized by low-suppressed secretion of aldosterone. Indeed, PY motifs are recognized by the ubiquitin ligase Nedd4. The binding of Nedd4 to the PY motifs of ENaC results in ubiquitination of apical ENaC, which elicits the internalization and degradation of ENaC. [29] [30] [31] The decrease in apical ENaC density results in reduced reabsorption of Na + . The ENaC mutations reported in LS are clustered in very short segments of the COOH-termini of either β or γ subunits. These mutations, which consist in either deletion or alteration of the PY motif, prevent Nedd4 binding to ENaC, so impairing ubiquitination-internalization-degradation of ENaC. The resulting increase in the ENaC density in the apical surface of the distal nephron 29, [32] [33] [34] leads to a greater Na + reabsorption, plasma volume expansion, and decrease in renin and aldosterone secretion. Na + reabsorption through ENaC generates a transepithelial lumen-negative voltage that drives K + secretion through its specific channels in the principal cells and facilitates the active proton secretion by the proton pump in the intercalated cells of the ASDN, resulting in hypokalemic alkalosis. However, a variable penetrance of hypokalemia has occasionally been found among patients with LS belonging to the same kindred. 2, 19, 35 We have previously reported a novel mutation (βP617L) of ENaC, resulting in the typical phenotype of LS, which included hypokalemic alkalosis, in a Sicilian patient. Functional expression in Xenopus laevis oocytes showed a threefold increase in the amiloride-sensitive Na + current in the oocytes expressing the mutant (βP617L) ENaC compared to those expressing wild-type ENaC. 27 The aim of the present study was to analyze the clinical and biochemical phenotype of a second family, also of Sicilian origin, carrying the βP617L mutation.
Subjects. Clinical, biochemical, and genetic analyses were performed in the proband, his mother, his maternal uncle, his maternal grandmother, and his father. Mitochondrial DNA (mtDNA) and Y chromosome analyses were also performed on the individual in which the βP617L mutation was first observed 27 and, as regards mtDNA, on his mother and his paternal aunt. This study was approved by the Provincial Ethical Committee of Reggio Emilia, and all participating subjects gave their informed consent.
Biochemical measurements. Aldosterone was measured using a solid-phase 125 I RIA kit (Immunotech-Beckman Coulter, Marseille, France). Quantitative analysis of urinary-free cortisol and free cortisone was performed using a solid-phase extraction column and high-performance liquid chromatography with UV detection. 36 Other biochemical and hormonal measurements were performed using standard methods.
DNA sequencing. Genomic DNA was extracted using a rapid extraction kit (Puregene extraction kit D-40K; Gentra System, Minneapolis, MN) from 300 µl of peripheral leukocytes by standard methods. PCR amplified two DNA fragments corresponding to coding sequences of the C-terminal exons of SCNN1B gene (from codon 515-640) and SCNN1G gene (from codon 523 to 648). Particularly, the SCNN1B amplicon (fragment size 463 bp) spans from 30 bp of final part of intron 12-13 to exon 13 comprising 52 bp of 3′ untranslated region, the SCNN1G amplicon (fragment size 432 bp) includes 29 bp of intron 12-13 and 403 bp of exon13 (entire coding region plus 22 bp of 3′-untranslated region). PCR primers for SCNN1B (sense 5′-GAGCTCACCCCAGCT CCCTG-3′, antisense 5′-CAGTCTTGGCTGCTCAGTGAG-3′) and SCNN1G (sense 5′-TTGATGGTGTGGCTTGGCCTG-3′, antisense 5′-GATCTGTCTTCTCAAACCCTGC-3′) were designed using Web Primer (http://seq.yeastgenome.org/cgibin/web-primer).
PCR products were purified and subjected to dye terminator cycle sequencing with the DTCS cycle sequencing kit (Beckman Coulter, Fullerton, CA). Separation by capillary electrophoresis was performed with an 8-capillary-array CEQ2000XL DNA sequencer (Beckman Coulter). Sequencing reaction was repeated twice using two amplification products to confirm the test.
Restriction fragment length polymorphism of the final exon of the βENaC gene. The direct sequencing of the final sequence of the SCNN1B identified a mutation at codon 617 in the proband, in the proband's mother, in the proband's maternal uncle and in the proband's maternal grandmother, but not in the proband's father. Within the amplicon obtained from the SCNN1B gene, point mutation C1850T creates a BsrBI restriction site (CCGCTC); thus, this enzyme can reveal the presence of T or C nucleotide at position 1,850 of SCNN1B transcript corresponding to the second base of codon 617 of reference sequence NP_000327 (NCBI and SwissProt). The PCR product of 463 bp was cleaved into two fragments of 336 and 127 bp only if it contained the mutation at codon 617. Therefore, after sequence analysis, we also analyzed the amplicons obtained from the proband, his mother, maternal uncle, maternal grandmother, and his father DNA by PCR restriction fragment length polymorphism method to confirm the presence of point mutation. We performed digestion of an aliquot of 10-µl PCR products using BsrBI restriction endonuclease (New England Biolabs, Ipswich, MA) followed by electrophoresis in 2% agarose gel stained with ethidium bromide (0.5 µg/ml). Finally the gel was visualized under UV light to evaluate digested PCR products. Sequencing reaction was repeated using the H155 primer to sequence the HVRI region in both directions. Products were precipitated using ethanol, dried, and resuspended in 30 µl of deionized formamide to be analyzed on an ABI Prism 3730 Genetic Analyzer (Applied Biosystems). The DNA_Aligment 1.3.1.1 software was used to align sequences to the mtDNA reference sequence (rCRS) for detecting polymorphic sites. Haplogroups for each individual were inferred by matching HVSI haplotypes with the most recent literature data from mtDNA tree Build 10 (http://www.phylotree.org/) and the mtDNA manager database (http://mtmanager.yonsei.ac.kr/).
A 17 Y chromosome short tandem repeats profile was obtained using the AmpF lSTR Y-Filer kit (Applied Biosystems). 37, 38 PCRs were performed in a 5-µl reaction volume with 1 ng DNA and a fivefold reduction of reagents volume respect to the manufacturer's instructions. Products were run on an ABI Prism 3130 Genetic Analyzer (Applied Biosystems) and allele identification was performed by the GeneMapper ID 3.2 Software (Applied Biosystems). Haplogroups were inferred with the 23-Haplogroup Beta Program Haplogroup Predictor (http:// www.hprg.com/hapest5/) and subsequently confirmed by genotyping eight single-nucleotide polymorphisms included in the MY1 multiplex. 39 
results clinical findings
The proband, a 21-year-old male, had been hypertensive from the age of 17 years. Early onset hypertension characterized seven members of the maternal line across three generations, which suggested an autosomal-dominant inheritance (Figure 1) . The proband's maternal kindred was of Sicilian origin, as was the family carrying the same mutation previously reported by our group, despite no apparent relationship between them. Pretreatment clinical findings in the proband and in his three relatives with juvenile hypertension available for examination are shown in Table 1 . The time lapse between the ascertainment of hypertension and the diagnosis of LS turned out to be 4 years in the proband, 10 years in his maternal uncle, 30 years in his mother, and 49 years in his grandmother. The severity of hypertension was variable from grade 1 to 3. Each of the four subjects presented concentric left ventricular hypertrophy. None of the subjects showed either low levels of plasma K + or a history of hypokalemia. Apparent mineralocorticoid excess syndrome was excluded in the proband on the basis of a normal urine free cortisol (nmol)-to-cortisone (nmol) ratio (0.50, normal range 0.23-0.75). All of them showed suppression of both renin and aldosterone. Treatment with amiloride (at a daily dose variable from 5 to 15 mg) resulted in normalization of blood pressure and in an increase in both renin and aldosterone levels in the proband, in his mother, and maternal grandmother. Urinary aldosteroneto-potassium ratios before amiloride therapy were very low, like those reported in other patients with LS, 2 and increased six-and fourfold in the proband and his mother, respectively, following amiloride treatment ( Table 1) . The proband's maternal uncle declined treatment and follow-up.
Molecular findings
Sequencing analysis detected a heterozygous C to T mutation at codon 617 in exon 13 of SCNN1B in the proband and in all of the members of the maternal lineage submitted to genetic analysis (Figure 2 ). This mutation is predicted to replace the second proline with leucine in the PY motif of the β subunit (P617L). Restriction enzyme polymorphism analysis was consistent with the sequencing analysis (Figure 3) . No variant of γ-subunit of ENaC was detected.
Since both the proband's maternal kindred and the family of the individual in whom we first observed the βP617L mutation were of Sicilian origin, mtDNA and Y chromosome profiles were also investigated in the attempt to establish whether an unknown biological relationship exists between these families. mtDNA HVRI sequencing analysis pointed out different polymorphic sites between haplotypes of the proband family and those of the other family, leading to the inference of two completely distinct maternal lineages, U5b and M1, respectively ( Table 2) . Similarly, the examined families were not related as to the paternal lineages (J1 and I1, respectively), according to Y chromosome profiles which diverged for the number of repeated alleles in almost all the examined short tandem repeats loci ( Table 2) .
discussion
Each of the four examined carriers of the βP617L mutation in this family suffered from early onset hypertension, as was observed in most cases of LS reported so far. However, severity of hypertension was variable, ranging from severe in the proband to mild in his three available relatives with LS. All of them showed completely normal values of plasma potassium concentration.
Phenotypic variability of LS has already been reported in association with some of the mutations identified so far. Indeed, blood pressure levels may vary from severe hypertension to normotension, whereas plasma potassium concentration may range from severe hypokalemia to normal values among patients with LS belonging to the same kindred. 2 original contributions
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However, most mutations responsible for LS have been found only in hypokalemic subjects, which may suggest that some specific ENaC mutations could invariably be associated with hypokalemia. Our finding of completely normal plasma potassium levels in all of the available carriers of the βP617L mutation in the present family, as opposed to the severe hypokalemia in an unrelated carrier of the same mutation previously reported by our group, 27 clearly demonstrates the prominent variability of the plasma potassium values associated with this mutation. Several mechanisms could account for normokalaemia in some patients with LS despite an increased activity of ENaC. Firstly, allele-specific effects on ENaC activity could play a role. Indeed, functional expression of different ENaC mutants in Xenopus laevis oocytes reveals allele-specific increases in ENaC activity, 18 which could differently affect potassium secretion and consequently plasma potassium level. Actually, allele-specific effects do not seem to play a major role in the case of βP617L mutation, given the impressive difference in plasma potassium levels between the present family and the carrier of the same mutation previously reported. Secondly, normokalemia does not exclude a mild to moderate intracellular potassium depletion, because the relationship between plasma potassium concentration and intracellular potassium concentration is not linear. To our knowledge, no measurement of the intracellular content of potassium in normokalemic patients with LS or other forms of mineralocorticoid hypertension has been performed so far. Thirdly, since potassium secretion in the distal nephron depends not only on the activity of ENaC but also on the sodium delivery to the distal nephron, a reduced dietary intake of sodium could limit potassium excretion in any form of mineralocorticoid hypertension. Fourthly, an increased dietary potassium intake could also limit the degree of hypokalemia, especially in the presence of aldosterone suppression, as happens in LS. Finally, allelic variants of other genes affecting renal potassium handling could contribute to the variability of plasma potassium levels. Suppression of both renin and aldosterone, which is the common biochemical hallmark of all mineralocorticoid forms of hypertension except primary aldosteronism, was the only shared feature in this family with LS, as well as in most of the other families with LS reported so far.
The finding of normokalemia in the proband challenges the common diagnostic process for identifying patients with LS. Indeed, all of the other normokalemic LS patients previously reported were identified through a screening of relatives of hypokalemic probands. This implies that LS is currently considered only in hypokalemic hypertensives and subsequently in their relatives, and that normokalemic patients with LS are identified only following the demonstration of LS in one hypokalemic relative. Therefore, the current approach may fail to identify and treat many normokalemic patients with LS and many years may pass before LS in the normokalemic relatives of hypokalemic probands is properly diagnosed. Thus, although LS is considered a very rare condition, it may well be underdiagnosed, due to the shortcomings of the current diagnostic approach. Similarly, a high proportion of patients with other forms of actual (e.g., primary aldosteronism) or apparent mineralocorticoid excess would be missed if hypokalemia were used as a sine qua non for the diagnostic workup. In particular, screening of hypertensives for primary aldosteronism regardless of the plasma potassium values has impressively increased the prevalence of this condition.
The proband's maternal kindred was of Sicilian origin, as was the family carrying the same mutation previously reported by our group. 27 Although the two families involved are unaware of any blood ties between them, an unknown biological relationship could have existed between them. Therefore, mtDNA and Y chromosome analyses were performed in the proband and in the individual in which the βP617L mutation was first observed, as well as in some of their relatives, to exclude such hypothesis. Because of their lack of recombination, uniparental patterns of inheritance and high geographical structure, mtDNA and Y chromosome neutral markers are indeed widely used for reconstructing female-and male-specific haplotype phylogenies which can be successfully related to the geographic distribution of different lineages. 40 The complementary information provided by such analyses conclusively confirmed the absence of a close biological relation between the two families under investigation. However, both the rarity of LS and the lack of other reports of the βP617L mutation, as well as the shared geographical origin of the two kindreds, may suggest a founder mutation. On the other hand, the availability of only one carrier of the mutation in one of the two families means that a genetic analysis to assess a founder effect cannot be performed. For this purpose, specific haplotype segregation patterns of polymorphic markers located in the proximity of the βP617L mutation should have been investigated within the two different pedigrees; unfortunately, no βP617L carriers were present among the available relatives of one of the two probands, thus forbidding the analysis mentioned above. Thus, although we could not prove the hypothesis that the βP617L mutation may have arisen as a consequence of a founder effect in the Sicilian population, this possibility cannot be ruled out a priori.
LS should be considered in all cases of juvenile hypertension, regardless of either the plasma potassium concentration or the severity of hypertension.
Therefore, measurement of renin and aldosterone levels should be recommended in all cases of early onset hypertension. This preliminary screening may allow one to exclude or ascertain various forms of mineralocorticoid hypertension, including primary aldosteronism.
Suppression of both renin and aldosterone in young hypertensives without signs of virilization or hypogonadism should prompt the measurement of the urinary free cortisol-to-cortisone ratio and molecular analysis of the last exons of the β-and γ-subunits of ENaC in order to exclude apparent mineralocorticoid excess syndrome and LS, respectively.
Since the mutations causing LS are all clustered in very short segments of the COOH-termini of either β-or γ-subunit of ENaC, DNA analysis is a sensitive, rapid, simple, and feasible diagnostic tool to confirm or exclude LS.
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At present, the diagnosis of LS is considered only in young hypokalemic hypertensives and in the relatives of hypokalemic probands. This approach may fail to detect and appropriately treat many patients with LS with a high risk of cardiovascular complications. Finally, as hypokalemia is not a universal finding in LS, the incidence of LS may be greater than is currently thought.
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